DermaSensor

DermaSensor is a commercial-stage diagnostics company offering an FDA-cleared, AI-driven device for non-invasive skin cancer detection at the point of care. Its handheld tool utilizes elastic scattering spectroscopy (ESS) and proprietary algorithms to analyze lesions for melanoma, basal cell carcinoma, and squamous cell carcinoma, providing a risk assessment in seconds with reported 96% accuracy. The company targets primary care physicians, internists, and other non-specialists to address long dermatology wait times and improve early detection rates. DermaSensor is actively commercializing its device in the US, offering reimbursement assistance and positioning itself at the intersection of AI, diagnostics, and dermatology.

Handheld device combining Elastic Scattering Spectroscopy (ESS) and proprietary machine learning algorithms for non-invasive, point-of-care analysis of skin lesions.

DermaSensor competes in the emerging AI dermatology diagnostics space. Competitors include software-only teledermatology and AI analysis apps (e.g., FotoFinder, SkinVision) and other hardware-based spectroscopic devices in development. Its key differentiation is its FDA clearance as a handheld device providing immediate, point-of-care results, positioning it as an adjunct for non-specialist clinicians rather than a direct-to-consumer or dermatologist-only tool.